Preclinical evidence suggests that the use of ATRis such as AZD6738 or CHK1 inhibitors like AZD7762 can synergize with radiation or PD-1 blockade to stimulate anti-tumor immunity and delay tumor progression. This evidence concerns the gene CHEK1 and neoplasm.